These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson's disease. Fabbrini G; Juncos J; Mouradian MM; Serrati C; Chase TN Ann Neurol; 1987 Apr; 21(4):370-6. PubMed ID: 3579222 [TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease. Adamiak U; Kaldonska M; Klodowska-Duda G; Wyska E; Safranow K; Bialecka M; Gawronska-Szklarz B Clin Neuropharmacol; 2010 May; 33(3):135-41. PubMed ID: 20216409 [TBL] [Abstract][Full Text] [Related]
10. Repeated levodopa infusions in fluctuating Parkinson's disease: clinical and pharmacokinetic data. Marion MH; Stocchi F; Quinn NP; Jenner P; Marsden CD Clin Neuropharmacol; 1986; 9(2):165-81. PubMed ID: 3708602 [TBL] [Abstract][Full Text] [Related]
11. Motor fluctuations during continuous levodopa infusions in patients with Parkinson's disease. Nutt JG; Carter JH; Lea ES; Woodward WR Mov Disord; 1997 May; 12(3):285-92. PubMed ID: 9159720 [TBL] [Abstract][Full Text] [Related]
12. Concentration-effect relationship of levodopa in patients with Parkinson's disease. Harder S; Baas H; Rietbrock S Clin Pharmacokinet; 1995 Oct; 29(4):243-56. PubMed ID: 8549026 [TBL] [Abstract][Full Text] [Related]
13. Motor fluctuations in Parkinson's disease: pathogenetic and therapeutic studies. Mouradian MM; Juncos JL; Fabbrini G; Chase TN Ann Neurol; 1987 Oct; 22(4):475-9. PubMed ID: 3435068 [TBL] [Abstract][Full Text] [Related]
14. Effects of tolcapone, a catechol-O-methyltransferase inhibitor, on motor symptoms and pharmacokinetics of levodopa in patients with Parkinson's disease. Yamamoto M; Yokochi M; Kuno S; Hattori Y; Tsukamoto Y; Narabayashi H; Tohgi H; Mizuno Y; Kowa H; Yanagisawa N; Kanazawa I J Neural Transm (Vienna); 1997; 104(2-3):229-36. PubMed ID: 9203084 [TBL] [Abstract][Full Text] [Related]
15. A comparison of the effects of controlled-release levodopa (Madopar CR) with conventional levodopa in late Parkinson's disease. MacMahon DG; Sachdev D; Boddie HG; Ellis CJ; Kendal BR; Blackburn NA J Neurol Neurosurg Psychiatry; 1990 Mar; 53(3):220-3. PubMed ID: 2182781 [TBL] [Abstract][Full Text] [Related]
17. Jejunal Infusion of levodopa-carbidopa intestinal gel versus oral administration of levodopa-carbidopa tablets in japanese subjects with advanced Parkinson's disease: pharmacokinetics and pilot efficacy and safety. Othman AA; Chatamra K; Mohamed ME; Dutta S; Benesh J; Yanagawa M; Nagai M Clin Pharmacokinet; 2015 Sep; 54(9):975-84. PubMed ID: 25875940 [TBL] [Abstract][Full Text] [Related]
18. [Intravenous infusion of L-dopa: current prospective therapies]. Peppe A; De Angelis D; Tolli VS; Rizzo PA; Scoppetta C Riv Neurol; 1991; 61(5):197-200. PubMed ID: 1808680 [TBL] [Abstract][Full Text] [Related]
19. Peripheral pharmacokinetics of levodopa in untreated, stable, and fluctuating parkinsonian patients. Gancher ST; Nutt JG; Woodward WR Neurology; 1987 Jun; 37(6):940-4. PubMed ID: 3587644 [TBL] [Abstract][Full Text] [Related]
20. On-off response. Clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients. Shoulson I; Glaubiger GA; Chase TN Neurology; 1975 Dec; 25(12):1144-8. PubMed ID: 812004 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]